Barry W Rovner1, Robin J Casten. 1. Department of Psychiatry and Neurology, Jefferson Medical College, Jefferson Medical College, Philadelphia, PA 19107, USA. barry.rovner@jefferson.edu
Abstract
OBJECTIVE: To determine whether problem-solving treatment (PST) can prevent depressive disorders in patients with age-related macular degeneration (AMD). DESIGN:Two hundred six patients with AMD were randomly assigned to PST (n = 105) or usual care (n = 101). PST therapists delivered six PST sessions over 8 weeks in subjects' homes. MEASUREMENTS: Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition Diagnoses of Depressive Disorders, Hamilton Depression Rating Scale scores, and rates of relinquishing valued activities were assessed at 2 months for short-term effects and 6 months for maintenance effects. RESULTS: The 2-month incidence rate of depressive disorders in PST-treated subjects was significantly lower than controls (11.6% versus 23.2%, respectively; OR = 0.43; 95% CI [0.20, 0.95]). PST also reduced the odds of relinquishing a valued activity (OR = 0.48; 95% CI [0.25, 0.96]); this effect mediated the relationship between treatment group and depression. By 6 months most earlier observed benefits had diminished. Secondary analyses showed that a minimal level of depressive symptoms were disabling and predicted incident depressive disorders. CONCLUSION:PST prevented depressive disorders and loss of valued activities as a short-term treatment but these benefits were not maintained over time. To sustain PST's effect, an intervention that uses a problem-solving framework to enhance rehabilitative skills may be necessary.
RCT Entities:
OBJECTIVE: To determine whether problem-solving treatment (PST) can prevent depressive disorders in patients with age-related macular degeneration (AMD). DESIGN: Two hundred six patients with AMD were randomly assigned to PST (n = 105) or usual care (n = 101). PST therapists delivered six PST sessions over 8 weeks in subjects' homes. MEASUREMENTS: Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition Diagnoses of Depressive Disorders, Hamilton Depression Rating Scale scores, and rates of relinquishing valued activities were assessed at 2 months for short-term effects and 6 months for maintenance effects. RESULTS: The 2-month incidence rate of depressive disorders in PST-treated subjects was significantly lower than controls (11.6% versus 23.2%, respectively; OR = 0.43; 95% CI [0.20, 0.95]). PST also reduced the odds of relinquishing a valued activity (OR = 0.48; 95% CI [0.25, 0.96]); this effect mediated the relationship between treatment group and depression. By 6 months most earlier observed benefits had diminished. Secondary analyses showed that a minimal level of depressive symptoms were disabling and predicted incident depressive disorders. CONCLUSION: PST prevented depressive disorders and loss of valued activities as a short-term treatment but these benefits were not maintained over time. To sustain PST's effect, an intervention that uses a problem-solving framework to enhance rehabilitative skills may be necessary.
Authors: Jürgen Unützer; Wayne Katon; Christopher M Callahan; John W Williams; Enid Hunkeler; Linda Harpole; Marc Hoffing; Richard D Della Penna; Polly Hitchcock Noël; Elizabeth H B Lin; Patricia A Areán; Mark T Hegel; Lingqi Tang; Thomas R Belin; Sabine Oishi; Christopher Langston Journal: JAMA Date: 2002-12-11 Impact factor: 56.272
Authors: Jeffrey M Lyness; JaeHyun Kim; Wan Tang; Xin Tu; Yeates Conwell; Deborah A King; Eric D Caine Journal: Am J Geriatr Psychiatry Date: 2007-01-09 Impact factor: 4.105
Authors: Dennis S Charney; Charles F Reynolds; Lydia Lewis; Barry D Lebowitz; Trey Sunderland; George S Alexopoulos; Dan G Blazer; Ira R Katz; Barnett S Meyers; Patricia A Arean; Soo Borson; Charlotte Brown; Martha L Bruce; Christopher M Callahan; Mary E Charlson; Yeates Conwell; Bruce N Cuthbert; D P Devanand; Mary Jo Gibson; Gary L Gottlieb; K Ranga Krishnan; Sally K Laden; Constantine G Lyketsos; Benoit H Mulsant; George Niederehe; Jason T Olin; David W Oslin; Jane Pearson; Trudy Persky; Bruce G Pollock; Susan Raetzman; Mildred Reynolds; Carl Salzman; Richard Schulz; Thomas L Schwenk; Edward Scolnick; Jurgen Unutzer; Myrna M Weissman; Robert C Young Journal: Arch Gen Psychiatry Date: 2003-07
Authors: Martha L Bruce; Thomas R Ten Have; Charles F Reynolds; Ira I Katz; Herbert C Schulberg; Benoit H Mulsant; Gregory K Brown; Gail J McAvay; Jane L Pearson; George S Alexopoulos Journal: JAMA Date: 2004-03-03 Impact factor: 56.272
Authors: Hilde P A van der Aa; Mirke Hoeben; Linda Rainey; Ger H M B van Rens; Hilde L Vreeken; Ruth M A van Nispen Journal: Qual Life Res Date: 2014-11-15 Impact factor: 4.147
Authors: George S Alexopoulos; Patrick J Raue; Dimitris N Kiosses; R Scott Mackin; Dora Kanellopoulos; Charles McCulloch; Patricia A Areán Journal: Arch Gen Psychiatry Date: 2011-01
Authors: Xinzhi Zhang; Kai McKeever Bullard; Mary Frances Cotch; M Roy Wilson; Barry W Rovner; Gerald McGwin; Cynthia Owsley; Lawrence Barker; John E Crews; Jinan B Saaddine Journal: JAMA Ophthalmol Date: 2013-05 Impact factor: 7.389
Authors: Jordan F Karp; Mary Amanda Dew; Abdus S Wahed; Kelley Fitzgerald; Chloe A Bolon; Debra K Weiner; Jennifer Q Morse; Steve Albert; Meryl Butters; Ariel Gildengers; Charles F Reynolds Journal: Am J Geriatr Psychiatry Date: 2015-11-17 Impact factor: 4.105
Authors: Elizabeth A Corsentino; Kathryn Sawyer; Natalie Sachs-Ericsson; Dan G Blazer Journal: Am J Geriatr Psychiatry Date: 2009-02 Impact factor: 4.105